U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Clinical Guideline Centre (UK). Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease. London: Royal College of Physicians (UK); 2012 Aug. (NICE Clinical Guidelines, No. 148.)

Cover of Urinary Incontinence in Neurological Disease

Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.

Show details

Reference list

1.
National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute for Health and Clinical Excellence; 2009. Available from: http://www​.nice.org.uk​/aboutnice/howwework​/developingniceclinicalguidelines​/clinicalguidelinedevelopmentmethods​/GuidelinesManual2009.jsp. [PubMed: 27905714]
2.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials. 1989;10(4):407–415. [PubMed: 2691207]
3.
Schunemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH. Measurement properties and interpretability of the Chronic Respiratory disease Questionnaire (CRQ). COPD. 2005;2(1):81–89. [PubMed: 17136967]
4.
Schunemann HJ, Guyatt GH. Goodbye M(C)ID! Hello MID, where do you come from? Health Services Research. 2005;40(2):593–597. [PMC free article: PMC1361157] [PubMed: 15762909]
5.
GRADE Working Group. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group website. 2011. [Last accessed: 1 October 2011].
6.
Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Archives of Physical Medicine and Rehabilitation. 2007;88(5):646–652. [PubMed: 17466735]
7.
Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2011. [Last accessed: 16 January 2011]. Available from: http://www​.oecd.org/std/ppp.
8.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourology and Urodynamics. 2002;21(2):167–178. [PubMed: 11857671]
9.
Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourology and Urodynamics. 2002;21(3):261–274. [PubMed: 11948720]
10.
Fowler C, Panicker J, Drake M, Harris C, Harrison S, Kirby M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2009;80(5):470–477. [PubMed: 19372287]
11.
Stohrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del PG, Kramer G, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. European Urology. 2009;56(1):81–88. [PubMed: 19403235]
12.
Department of Health. NHS Reference Costs 2009–2010. London: Department of Health; 2011.
13.
Bauer SB, Hallett M, Khoshbin S, Lebowitz RL, Winston KR, Gibson S, et al. Predictive value of urodynamic evaluation in newborns with myelodysplasia. Journal of the American Medical Association. 1984;252(5):650–652. [PubMed: 6737668]
14.
McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. Journal of Urology. 1981;126(2):205–209. [PubMed: 7196460]
15.
Seki N, Akawanza K, Senoh K. An analysis of risk factors for upper urinary tract deterioration in patients with myelodysplasia. BJU International. 1999;84(6):679–682. [PubMed: 10510115]
16.
Sidi AA, Dykstra DD, Gonzalez R. The value of urodynamic testing in the management of neonates with myelodysplasia: a prospective study. Journal of Urology. 1986;135(1):90–93. [PubMed: 3941475]
17.
Galloway NT, Mekras JA, Helms M, Webster GD. An objective score to predict upper tract deterioration in myelodysplasia. Journal of Urology. 1991;145(3):535–537. [PubMed: 1997704]
18.
McLorie GA, Perez-Marero R, Csima A, Churchill BM. Determinants of hydronephrosis and renal injury in patients with myelomeningocele. Journal of Urology. 1988;140(5 Pt 2):1289–1292. [PubMed: 3184306]
19.
Wang QW, Wen JG, Song DK, Su J, Che YY, Zhang P, et al. Is it possible to use urodynamic variables to predict upper urinary tract dilatation in children with neurogenic bladder-sphincter dysfunction? BJU International. 2006;98(6):1295–1300. [PubMed: 17034510]
20.
Khanna R, Sandhu AS, Doddamani D. Urodynamic management of neurogenic bladder in spinal cord injury. Medical Journal Armed Forces India. 2009;65(4):300–304. [PMC free article: PMC4921373] [PubMed: 27408280]
21.
Kim YH, Kattan MW, Boone TB. Bladder leak point pressure: the measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia. Journal of Urology. 1998;159(2):493–496. [PubMed: 9649270]
22.
Blaivas JG, Barbalias GA. Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. Journal of Urology. 1984;131(1):91–94. [PubMed: 6690756]
23.
de Filippo RE, Shaul DB, Harrison EA, Xie HW, Hardy BE. Neurogenic bladder in infants born with anorectal malformations: comparison with spinal and urologic status. Journal of Pediatric Surgery. 1999;34(5):825–827. [PubMed: 10359188]
24.
Lemack G, Frohman E, Ramnarayan P. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. Urology. 2007;69(5):893–897. [PubMed: 17482929]
25.
Lopez Pereira P, Moreno Valle JA, Espinosa L, Alonso Dorrego JM, Martinez Urrutia MJ, Lobato Romera R, et al. Are urodynamic studies really needed during bladder augmentation follow-up? Journal of Pediatric Urology. 2009;5(1):30–33. [PubMed: 18774747]
26.
Singhania P, Adankar MJ, Pathak HR. Urodynamic evaluation of urinary disturbances following traumatic brain injury. Urologia Internationalis. 2010;84(1):89–93. [PubMed: 20173376]
27.
Chao R, Mayo ME. Long-term urodynamic follow up in pediatric spinal cord injury. Paraplegia. 1994;32(12):806–809. [PubMed: 7708420]
28.
Generao SE, Dall’era JP, Stone AR, Kurzrock EA. Spinal cord injury in children: long-term urodynamic and urological outcomes. Journal of Urology. 2002;172(3):1092–1094. [PubMed: 15311046]
29.
Kessler TM. Predictive value of initial urodynamic pattern on urinary continence in patients with myelomeningocele. Neurourology and Urodynamics. 2006;25(4):361–367. [PubMed: 16721816]
30.
Wang SC, McGuire EJ, Bloom DA. A bladder pressure management system for myelodysplasia: clinical outcome. Journal of Urology. 1988;140(6):1499–1502. [PubMed: 3193522]
31.
Nosseir M, Hinkel A, Pannek J. Clinical usefulness of urodynamic assessment for maintenance of bladder function in patients with spinal cord injury. Neurourology and Urodynamics. 2007;26(2):228–233. [PubMed: 16998859]
32.
Cardenas DD, Hoffman JM, Kelly E, Mayo ME. Impact of a urinary tract infection educational program in persons with spinal cord injury. Journal of Spinal Cord Medicine. 2004;27(1):47–54. [PubMed: 15156937]
33.
Hagglund KJ, Clark MJ, Schopp LH, Sherman AK, Acuff ME. Consumer-assistant education to reduce the occurrence of urinary tract infections among persons with spinal cord injury. Topics in Spinal Cord Injury Rehabilitation. 2005;10(3):53–62.
34.
Anderson TP, Newman E, Dryja R, Price M. Urinary tract care: improvement through patient education. Archives of Physical Medicine and Rehabilitation. 1983;64(7):314–316. [PubMed: 6860108]
35.
Barber DB, Woodard FL, Rogers SJ, Able AC. The efficacy of nursing education as an intervention in the treatment of recurrent urinary tract infections in individuals with spinal cord injury. SCI Nursing. 1999;16(2):54–56. [PubMed: 10647489]
36.
Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. British Journal of Pharmacology. 2006;148(5):565–578. [PMC free article: PMC1751864] [PubMed: 16751797]
37.
Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. Journal of Urology. 2000;164(3 Pt 1):692–697. [PubMed: 10953127]
38.
Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU International. 2001;88(6):511–525. [PubMed: 11678743]
39.
Eustice S, Roe B, Paterson J. Prompted voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev. 2000;(2):CD002113. [PMC free article: PMC7017853] [PubMed: 10796861]
40.
Ostaszkiewicz J, Chestney T, Roe B. Habit retraining for the management of urinary incontinence in adults. Cochrane Database Syst Rev. 2004;(2):CD002801. [PMC free article: PMC8078200] [PubMed: 15106179]
41.
van Houten P, Achterberg W, Ribbe M. Urinary incontinence in disabled elderly women: a randomized clinical trial on the effect of training mobility and toileting skills to achieve independent toileting. Gerontology. 2007;53(4):205–210. [PubMed: 17347567]
42.
Curtis L. Personal Social Services Research Unit. Unit costs of health and social care. Canterbury: University of Kent; 2010.
43.
Fader M, Glickman S, Haggar V, Barton R, Brooks R, Malone-Lee J. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. Journal of Urology. 2007;177(1):208–213. [PubMed: 17162046]
44.
Gajewski J, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. Journal of Urology. 1986;135(5):966–968. [PubMed: 3959249]
45.
Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, doubleblind, multicentre trial in the treatment of detrusor hyper-reflexia. British Journal of Urology. 1995;75(4):452–456. [PubMed: 7788255]
46.
Stohrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: a double-blind, placebo-controlled clinical trial. Spinal Cord. 1999;37(3):196–200. [PubMed: 10213329]
47.
Stohrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ. Propiverine compared to oxybutynin in neurogenic detrusor overactivity: results of a randomized, double-blind, multicenter clinical study. European Urology. 2007;51(1):235–242. [PubMed: 16698176]
48.
Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. European Urology. 1998;34(2):148–153. [PubMed: 9693251]
49.
Baskin LS, Kogan BA, Benard F. Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. British Journal of Urology. 1990;66(5):532–534. [PubMed: 2249125]
50.
Connor JP, Betrus G, Fleming P, Perlmutter AD, Reitelman C. Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients. Journal of Urology. 1994;151(4):1045–1047. [PubMed: 8126787]
51.
Ferrara P, d’Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU International. 2001;87(7):674–677. [PubMed: 11350411]
52.
Franco I, Horowitz M, Grady R, Adams R, de Jong TP, Lindert K, et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. Journal of Urology. 2005;173(1):221–225. [PubMed: 15592080]
53.
Goessl C, Knispel HH, Fiedler U, Harle B, Steffen-Wilke K, Miller K. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology. 1998;51(1):94–98. [PubMed: 9457296]
54.
Hehir M, Fitzpatrick JM. Oxybutinin and the prevention of urinary incontinence in spina bifida. European Urology. 1985;11(4):254–256. [PubMed: 3899664]
55.
Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. Journal of Urology. 1996;156(2 Pt 2):753–756. [PubMed: 8683776]
56.
Madersbacher H, Murtz G, Alloussi S, Domurath B, Henne T, Korner I, et al. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU International. 2009;103(6):776–781. [PubMed: 19007380]
57.
Painter KA, Vates TS, Bukowski TP, Fleming P, Freedman AL, Smith CA, et al. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. Journal of Urology. 1996;156(4):1459–1462. [PubMed: 8808907]
58.
Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. Journal of Urology. 1997;157(2):638–640. [PubMed: 8996387]
59.
Reddy PP, Borgstein NG, Nijman RJ, Ellsworth PI. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. Journal of Pediatric Urology. 2008;4(6):428–433. [PubMed: 19013412]
60.
Schulte-Baukloh H, Murtz G, Henne T, Michael T, Miller K, Knispel HH. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. BJU International. 2006;97(2):355–358. [PubMed: 16430646]
61.
Amark P, Eksborg S, Juneskans O, Bussman G, Palm C. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. British Journal of Urology. 1998;82(6):859–864. [PubMed: 9883225]
62.
Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Scandinavian Journal of Urology and Nephrology. 2007;41(4):335–340. [PubMed: 17763227]
63.
Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. European Urology. 2011;60(4):742–750. [PubMed: 21798658]
64.
Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. Journal of Urology. 2011;185(6):2229–2235. [PubMed: 21497851]
65.
Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized double-blind trial. Neurourology and Urodynamics. 2009;28(7):608–609. [PubMed: 21497851]
66.
Schurch B, De S, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. Journal of Urology. 2005;174(1):196–200. [PubMed: 15947626]
67.
Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. European Urology. 2007;52(3):850–859. [PubMed: 17467889]
68.
Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006;68(6):1193–1197. [PubMed: 17141831]
69.
Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. Journal of Urology. 2011;185(4):1344–1349. [PubMed: 21334639]
70.
Pannek J, Gocking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin a injections on detrusor function in patients with neurogenic bladder dysfunction. BJU International. 2009;104(9):1246–1250. [PubMed: 19426192]
71.
Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. European Urology. 2007;52(6):1729–1735. [PubMed: 17884281]
72.
del Popolo G, Filocamo MT, li Marzi V, Macchiarella A, Cecconi F, Lombardi G, et al. Neurogenic detrusor overactivity treated with english botulinum toxin A: 8-year experience of one single centre. European Urology. 2008;53(5):1013–1020. [PubMed: 17950989]
73.
Giannantoni A, Mearini E, del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. European Urology. 2009;55(3):705–712. [PubMed: 18814955]
74.
Kuo H-C, Liu S-H. Effect of repeated detrusor onabotulinumtoxina injections on bladder and renal function in patients with chronic spinal cord injuries. Neurourology and Urodynamics. 2011;30(8):1541–1545. [PubMed: 21717505]
75.
Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. European Urology. 2005;47(5):653–659. [PubMed: 15826758]
76.
Neel KF, Soliman S, Salem M, Seida M, Al-Hazmi H, Khatab A. Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder. Journal of Urology. 2007;178(6):2593–2597. [PubMed: 17945300]
77.
Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. Journal of Urology. 2006;175(3):1102–1105. [PubMed: 16469632]
78.
Deshpande AV, Sampang R, Smith GH. Study of botulinum toxin A in neurogenic bladder due to spina bifida in children. ANZ Journal of Surgery. 2010;80(4):250–253. [PubMed: 20575951]
79.
Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH, et al. Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology. 2006;68(5):1091–1096. [PubMed: 17113899]
80.
Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L. Botulinum A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. Journal of Urology. 2004;171(2 Pt I):845–848. [PubMed: 14713840]
81.
Akbar M, Abel R, Seyler TM, Gerner HJ, Mohring K. Repeated botulinum A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU International. 2007;100(3):639–645. [PubMed: 17532858]
82.
Do Ngoc TC, Audry G, Forin V. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases. Journal of Pediatric Urology. 2009;5(6):430–436. [PubMed: 19577520]
83.
Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K. Repeated botulinum A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology. 2005;66(4):865–870. [PubMed: 16230156]
84.
Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH. Botulinum A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. European Urology. 2003;44(1):139–143. [PubMed: 12814690]
85.
Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of botulinum A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology. 2002;59(3):325–327. [PubMed: 11880062]
86.
Schurch B, Schulte-Baukloh H. Botulinum toxin in the treatment of neurogenic bladder in adults and children. European Urology, Supplements. 2006;5(11):679–684.
87.
Kalsi V, Popat R, Apostolidis A, Kavia R, Odeyemi IAO, Dakin HA, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. European Urology. 2006;49(3):519–527. [PubMed: 16413656]
88.
Wefer B, Ehlken B, Bremer J, Burgdorfer H, Domurath B, Hampel C, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World Journal of Urology. 2010;28(3):385–390. [PubMed: 19693509]
89.
Padmanabhan P, Scarpero H, Milam D, Dmochowski R, Penson D. Five year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. Journal of Urology. 2010;183(4 Suppl):e136. [PubMed: 21110030]
90.
Frankel HL, Coll JR, Charlifue SW, Whiteneck GG, Gardner BP, Jamous MA, et al. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord. 1998;36(4):266–274. [PubMed: 9589527]
91.
Reyblat P, Chan KG, Josephson DY, Stein JP, Freeman JA, Grossfeld GD, et al. Comparison of extraperitoneal and intraperitoneal augmentation enterocystoplasty for neurogenic bladder in spinal cord injury patients. World Journal of Urology. 2009;27(1):63–68. [PubMed: 19020878]
92.
Padmanabhan P, Scarpero H, Milam D, Dmochowski R, Penson D. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World Journal of Urology. 2011;29(1):51–57. [PubMed: 21110030]
93.
Arikan N, Ozdiler E, Yaman O, Gogus O. Augmentation duracystoplasty in neurogenic bladder dysfunction. International Journal of Urology. 1995;2(3):172–175. [PubMed: 8536133]
94.
Arikan N, lmez K, Budak M, Gogus O. Outcome of augmentation sigmoidocystoplasty in children with neurogenic bladder. Urologia Internationalis. 2000;64(2):82–85. [PubMed: 10810269]
95.
Beseghi U, Casolari E, del Rossi C, Ghinelli C. Enterocystoplasty with a sigmoid patch in children with neurogenic bladder dysfunction. Pediatric Surgery International. 1994;9(1–2):82–85.
96.
Chancellor MB, Karusick S, Erhard M, Abdill CK, Liu JB, Goldberg BB, et al. Placement of a wire mesh prosthesis in the external urinary sphincter of men with spinal cord injuries. Radiology. 1993;187(2):551–555. [PubMed: 8475306]
97.
Chen JL, Kuo HC. Long-term outcomes of augmentation enterocystoplasty with an ileal segment in patients with spinal cord injury. Journal of the Formosan Medical Association. 2009;108(6):475–480. [PubMed: 19515628]
98.
de Long WB, Polissar N, Neradilek B. Timing of surgery in cauda equina syndrome with urinary retention: meta-analysis of observational studies. Journal of Neurosurgery Spine. 2008;8(4):305–320. [PubMed: 18377315]
99.
Fiorica VM, Barnes WF. Augmentation enterocystoplasty in children with myelomeningocele. Journal of the Oklahoma State Medical Association. 1987;80(4):236–238. [PubMed: 3585583]
100.
Herschorn S, Hewitt RJ. Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology. 1998;52(4):672–678. [PubMed: 9763092]
101.
Kass EJ, Koff SA. Bladder augmentation in the pediatric neuropathic bladder. Journal of Urology. 1983;129(3):552–555. [PubMed: 6834546]
102.
Khastgir J, Hamid R, Arya M, Shah N, Shah PJ. Surgical and patient reported outcomes of ‘clam’ augmentation ileocystoplasty in spinal cord injured patients. European Urology. 2003;43(3):263–269. [PubMed: 12600429]
103.
Linder A, Leach GE, Raz S. Augmentation cystoplasty in the treatment of neurogenic bladder dysfunction. Journal of Urology. 1983;129(3):491–493. [PubMed: 6834530]
104.
Lockhart JL, Bejany D, Politano VA. Augmentation cystoplasty in the management of neurogenic bladder disease and urinary incontinence. Journal of Urology. 1986;135(5):969–971. [PubMed: 3959250]
105.
Lopez Pereira P, Moreno Valle JA, Espinosa L, Alonso Dorrego JM, Burgos-Lucena L, Martinez Urrutia MJ, et al. Enterocystoplasty in children with neuropathic bladders: long-term follow-up. Journal of Pediatric Urology. 2008;4(1):27–31. [PubMed: 18631888]
106.
MacNeily AE, Afshar K, Coleman GU, Johnson HW. Autoaugmentation by detrusor myotomy: its lack of effectiveness in the management of congenital neuropathic bladder. Journal of Urology. 2003;170(4 Pt 2):1643–1646. [PubMed: 14501681]
107.
Marte A, di Meglio D, Cotrufo AM, di Iorio G, de Pasquale M, Vessella A. A long-term follow-up of autoaugmentation in myelodysplastic children. BJU International. 2002;89(9):928–931. [PubMed: 12010242]
108.
McInerney PD, DeSouza N, Thomas PJ, Mundy AR. The role of urodynamic studies in the evaluation of patients with augmentation cystoplasties. British Journal of Urology. 1995;76(4):475–478. [PubMed: 7551885]
109.
Medel R, Ruarte AC, Herrera M, Castera R, Podesta ML. Urinary continence outcome after augmentation ileocystoplasty as a single surgical procedure in patients with myelodysplasia. Journal of Urology. 2002;168(4 Pt 2):1849–1852. [PubMed: 12352374]
110.
Metcalfe PD, Cain MP, Kaefer M, Gilley DA, Meldrum KK, Misseri R, et al. What is the need for additional bladder surgery after bladder augmentation in childhood? Journal of Urology. 2006;176(4 Pt 2):1801–1805. [PubMed: 16945653]
111.
Mitsui T, Tanaka H, Moriya K, Matsuda M, Nonomura K. Outcomes of lower urinary and bowel function in meningomyelocele patients with augmentation enterocystoplasty. Spinal Cord. 2008;46(6):432–437. [PubMed: 18317489]
112.
Nasrallah PF, Aliabadi H. Bladder augmentation in patients with neurogenic bladder and vesicoureteral reflux. Journal of Urology. 1991;146(2 Pt 2):563–566. [PubMed: 1861301]
113.
Nomura S, Ishido T, Tanaka K, Komiya A. Augmentation ileocystoplasty in patients with neurogenic bladder due to spinal cord injury or spina bifida. Spinal Cord. 2002;40(1):30–33. [PubMed: 11821967]
114.
Lopez Pereira P, Martinez Urrutia MJ, Lobato Romera R, Jaureguizar E. Should we treat vesicoureteral reflux in patients who simultaneously undergo bladder augmentation for neuropathic bladder? Journal of Urology. 2001;165(6 Pt II Suppl):2259–2261. [PubMed: 11371958]
115.
Quek ML, Ginsberg DA. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. Journal of Urology. 2003;169(1):195–198. [PubMed: 12478134]
116.
Radomski S, Herschorn S, Stone AR. Urodynamic comparison of ileum vs. sigmoid in augmentation cystoplasty for neurogenic bladder dysfunction. Neurourology and Urodynamics. 1995;14(3):231–237. [PubMed: 7647805]
117.
Sidi AA, Aliabadi H, Gonzalez R. Enterocystoplasty in the management and reconstruction of the pediatric neurogenic bladder. Journal of Pediatric Surgery. 1987;22(2):153–157. [PubMed: 3820015]
118.
Sidi AA, Becher EF, Reddy PK, Dykstra DD. Augmentation enterocystoplasty for the management of voiding dysfunction in spinal cord injury patients. Journal of Urology. 1990;143(1):83–85. [PubMed: 2294270]
119.
Simforoosh N, Tabibi A, Basiri A, Noorbala MH, Danesh AD, Ijadi A. Is ureteral reimplantation necessary during augmentation cystoplasty in patients with neurogenic bladder and vesicoureteral reflux? Journal of Urology. 2002;168(4 Pt 1):1439–1441. [PubMed: 12352413]
120.
Stohrer M, Kramer G, Goepel M, Lochner-Ernst D, Kruse D, Rubben H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord. 1997;35(7):456–462. [PubMed: 9232751]
121.
Stothers L, Johnson H, Arnold W, Coleman G, Tearle H. Bladder autoaugmentation by vesicomyotomy in the pediatric neurogenic bladder. Urology. 1994;44(1):110–113. [PubMed: 8042249]
122.
Sutton MA, Hinson JL, Nickell KG, Boone TB. Continent ileocecal augmentation cystoplasty. Spinal Cord. 1998;36(4):246–251. [PubMed: 9589524]
123.
Zachoval R, Pitha J, Medova E, Heracek J, Lukes M, Zalesky M, et al. Augmentation cystoplasty in patients with multiple sclerosis. Urologia Internationalis. 2003;70(1):21–26. [PubMed: 12566810]
124.
Chancellor MB, Erhard M, Strup S, Tammela TLJ. Bladder augmentation using the stomach in spinal cord injured patients with impaired renal function. Archives of Physical Medicine and Rehabilitation. 1993;74(11):1222–1224. [PubMed: 8239968]
125.
National Institute for Health and Clinical Excellence. Urinary incontinence: the management of urinary incontinence in women. London: National Institute for Health and Clinical Excellence; 2006. Available from: http://www​.nice.org.uk​/nicemedia/live/10996/30282/30282.pdf.
126.
Singh G, Thomas DG. Artificial urinary sphincter in patients with neurogenic bladder dysfunction. British Journal of Urology. 1996;77(2):252–255. [PubMed: 8800894]
127.
Lucio AC, Campos RM, Perissinotto MC, Miyaoka R, Damasceno BP, d’Ancona CA. Pelvic floor muscle training in the treatment of lower urinary tract dysfunction in women with multiple sclerosis. Neurourology and Urodynamics. 2010;29(8):1410–1413. [PubMed: 20976816]
128.
Vahtera T, Haaranen M, Viramo-Koskela AL, Ruutiainen J. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clinical Rehabilitation. 1997;11(3):211–219. [PubMed: 9360033]
129.
McClurg D, Lowe-Strong A, Ashe RG. The benefits of pelvic floor muscle training in people with multiple sclerosis and lower urinary tract dysfunction. Journal of the Association of Chartered Physiotherapists in Women’s Health. 2008;103:21–28.
130.
McClurg D, Ashe RG, Marshall K, Lowe-Strong A. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourology and Urodynamics. 2006;25(4):337–348. [PubMed: 16637070]
131.
Tibaek S, Gard G, Jensen R. Pelvic floor muscle training is effective in women with urinary incontinence after stroke: a randomised, controlled and blinded study. Neurourology and Urodynamics. 2005;24(4):348–357. [PubMed: 15791633]
132.
Tibaek S, Jensen R, Lindskov G, Jensen M. Can quality of life be improved by pelvic floor muscle training in women with urinary incontinence after ischemic stroke? A randomised, controlled and blinded study. International Urogynecology Journal. 2004;15(2):117–123. [PubMed: 15014939]
133.
Department of Health. NHSCat. UK: Department of Health; 2010. Available from: https://my​.supplychain.nhs.uk/catalogue.
134.
McClurg D, Ashe RG, Lowe-Strong A. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis: a double blind, placebo controlled, randomised clinical trial. Neurourology and Urodynamics. 2008;27(3):231–237. [PubMed: 17705160]
135.
Dean GE, Kunkle DA. Outpatient perineal sling in adolescent boys with neurogenic incontinence. Journal of Urology. 2009;182(4 Suppl):1792–1796. [PubMed: 19692039]
136.
Godbole P, Mackinnon AE. Expanded PTFE bladder neck slings for incontinence in children: the long-term outcome. BJU International. 2004;93(1):139–141. [PubMed: 14678386]
137.
Hamid R, Khastgir J, Arya M, Patel HR, Shah PJ. Experience of tension-free vaginal tape for the treatment of stress incontinence in females with neuropathic bladders. Spinal Cord. 2003;41(2):118–121. [PubMed: 12595875]
138.
Abdul-Rahman A, Attar KH, Hamid R, Shah PJ. Long-term outcome of tension-free vaginal tape for treating stress incontinence in women with neuropathic bladders. BJU International. 2010;106(6):827–830. [PubMed: 20132201]
139.
Herschorn S, Radomski S. Fascial slings and bladder neck tapering in the treatment of male neurogenic incontinence. Journal of Urology. 1992;147(4):1073–1075. [PubMed: 1552586]
140.
Daneshmand S, Ginsberg DA, Bennet JK, Foote J, Killorin W, Rozas KP, et al. Puboprostatic sling repair for treatment of urethral incompetence in adult neurogenic incontinence. Journal of Urology. 2003;169(1):199–202. [PubMed: 12478135]
141.
Barthold JS, Rodriguez E, Freedman AL, Fleming P, Gonzalez R. Results of the rectus fascial sling and wrap procedures for the treatment of neurogenic sphincteric incontinence. Journal of Urology. 1999;161(1):272–274. [PubMed: 10037423]
142.
Bugg CE Jr, Joseph DB. Bladder neck cinch for pediatric neurogenic outlet deficiency. Journal of Urology. 2003;170(4 Pt 2):1501–1503. [PubMed: 14501645]
143.
Dik P, van Gool JD, de Jong TP. Urinary continence and erectile function after bladder neck sling suspension in male patients with spinal dysraphism. BJU International. 1999;83(9):971–975. [PubMed: 10368238]
144.
Misseri R, Cain MP, Casale AJ, Kaefer M, Meldrum KK, Rink RC. Small intestinal submucosa bladder neck slings for incontinence associated with neuropathic bladder. Journal of Urology. 2005;174(4 Pt 2):1680–1682. [PubMed: 16148680]
145.
Snodgrass W, Keefover-Hicks A, Prieto J, Bush N, Adams R. Comparing outcomes of slings with versus without enterocystoplasty for neurogenic urinary incontinence. Journal of Urology. 2009;181(6):2709–2714. [PubMed: 19375730]
146.
Austin PF, Westney OL, Leng WW, McGuire EJ, Ritchey ML. Advantages of rectus fascial slings for urinary incontinence in children with neuropathic bladders. Journal of Urology. 2001;165(6 Pt 2):2369–2371. [PubMed: 11398778]
147.
Dik P, Klijn AJ, van Gool JD, de Jong TP. Transvaginal sling suspension of bladder neck in female patients with neurogenic sphincter incontinence. Journal of Urology. 2003;170(2 Pt 1):580–581. [PubMed: 12853835]
148.
McGuire EJ, Wang CC, Usitalo H, Savastano J. Modified pubovaginal sling in girls with myelodysplasia. Journal of Urology. 1986;135(1):94–96. [PubMed: 3510322]
149.
Nguyen HT, Bauer SB, Diamond DA, Retik AB. Rectus fascial sling for the treatment of neurogenic sphincteric incontinence in boys: is it safe and effective? Journal of Urology. 2001;166(2):658–661. [PubMed: 11458113]
150.
Snodgrass W, Barber T. Comparison of bladder outlet procedures without augmentation in children with neurogenic incontinence. Journal of Urology. 2010;184(4 Suppl):1775–1780. [PubMed: 20728128]
151.
Albouy B, Grise P, Sambuis C, Pfister C, Mitrofanoff P, Liard A. Pediatric urinary incontinence: evaluation of bladder wall wraparound sling procedure. Journal of Urology. 2007;177(2):716–719. [PubMed: 17222665]
152.
Bauer SB, Peters CA, Colodny AH, Mandell J, Retik AB. The use of rectus fascia to manage urinary incontinence. Journal of Urology. 1989;142(2 Pt 2):516–519. [PubMed: 2746770]
153.
Castellan M, Gosalbez R, Labbie A, Ibrahim E, Disandro M. Bladder neck sling for treatment of neurogenic incontinence in children with augmentation cystoplasty: long-term follow-up. Journal of Urology. 2005;173(6):2128–2131. [PubMed: 15879865]
154.
Decter RM. Use of the fascial sling for neurogenic incontinence: lessons learned. Journal of Urology. 1993;150(2 Pt 2):683–686. [PubMed: 8326622]
155.
Elder JS. Periurethral and puboprostatic sling repair for incontinence in patients with myelodysplasia. Journal of Urology. 1990;144(2 Pt 2):434–437. [PubMed: 2374217]
156.
Fontaine E, Bendaya S, Desert JF, Fakacs C, le Mouel MA, Beurton D. Combined modified rectus fascial sling and augmentation ileocystoplasty for neurogenic incontinence in women. Journal of Urology. 1997;157(1):109–112. [PubMed: 8976228]
157.
Walker RD, Erhard M, Starling J. Long-term evaluation of rectus fascial wrap in patients with spina bifida. Journal of Urology. 2000;164(2):485–486. [PubMed: 10893629]
158.
Snodgrass W, Barber T, Cost N. Detrusor compliance changes after bladder neck sling without augmentation in children with neurogenic urinary incontinence. Journal of Urology. 2010;183(6):2361–2366. [PubMed: 20400137]
159.
Sidi AA, Reinberg Y, Gonzalez R. Comparison of artificial sphincter implantation and bladder neck reconstruction in patients with neurogenic urinary incontinence. Journal of Urology. 1987;138(4 Pt 2):1120–1122. [PubMed: 3656572]
160.
Aaronson IA. The AS 800 artificial urinary sphincter in children with myelodysplasia: preliminary results. South African Medical Journal. 1986;69(11):686–688. [PubMed: 3704860]
161.
Aprikian A, Berardinucci G, Pike J, Kiruluta G. Experience with the AS-800 artificial urinary sphincter in myelodysplastic children. Canadian Journal of Surgery. 1992;35(4):396–400. [PubMed: 1498739]
162.
Barrett DM, Furlow WL. The management of severe urinary incontinence in patients with myelodysplasia by implantation of the AS 791/792 urinary sphincter device. Journal of Urology. 1982;128(3):484–486. [PubMed: 7120551]
163.
Belloli G, Campobasso P, Mercurella A. Neuropathic urinary incontinence in pediatric patients: management with artificial sphincter. Journal of Pediatric Surgery. 1992;27(11):1461–1464. [PubMed: 1479510]
164.
Bersch U, Gocking K, Pannek J. The artificial urinary sphincter in patients with spinal cord lesion: description of a modified technique and clinical results. European Urology. 2009;55(3):687–693. [PubMed: 18394784]
165.
Bitsch M, Nerstrom H, Nordling J, Hald T. Upper urinary tract deterioration after implantation of artificial urinary sphincter. Scandinavian Journal of Urology and Nephrology. 1990;24(1):31–34. [PubMed: 2320970]
166.
Scott FB, Bradley WE, Timm GW, Kothari D. Treatment of incontinence secondary to myelodysplasia by an implantable prosthetic urinary sphincter. Southern Medical Journal. 1973;66(9):987–990. [PubMed: 4582131]
167.
Scott FB, Fishman IJ, Shabsigh R. The impact of the artificial urinary sphincter in the neurogenic bladder on the upper urinary tracts. Journal of Urology. 1986;136(3):636–642. [PubMed: 3735539]
168.
Chartier-Kastler E, Genevois S, Game X, Denys P, Richard F, Leriche A, et al. Treatment of neurogenic male urinary incontinence related to intrinsic sphincter insufficiency with an artificial urinary sphincter: a French retrospective multicentre study. BJU International England. 2011;107(3):426–432. [PubMed: 20633005]
169.
de Badiola FIP, Castro-Diaz D, Hart-Austin C, Gonzalez R. Influence of preoperative bladder capacity and compliance on the outcome of artificial sphincter implantation in patients with neurogenic sphincter incompetence. Journal of Urology. 1992;148(5 Pt I):1493–1495. [PubMed: 1433555]
170.
Gonzalez R, Merino FG, Vaughn M. Long-term results of the artificial urinary sphincter in male patients with neurogenic bladder. Journal of Urology. 1995;154(2 Pt 2):769–770. [PubMed: 7609175]
171.
Gonzalez R, Sheldon C. Artificial sphincters in children with neurogenic bladders: long-term results. Journal of Urology. 1982;128(6):1270–1272. [PubMed: 7154183]
172.
Gonzalez R, Dewolf WC. The artificial bladder sphincter AS-721 for the treatment of incontinence in patients with neurogenic bladder. Journal of Urology. 1979;121(1):71–72. [PubMed: 759648]
173.
Jakobsen H, Hald T. Management of neurogenic urinary incontinence with AMS artificial urinary sphincter. Scandinavian Journal of Urology and Nephrology. 1986;20(2):137–141. [PubMed: 3749818]
174.
Light JK, Scott FB. Use of the artificial urinary sphincter in spinal cord injury patients. Journal of Urology. 1983;130(6):1127–1129. [PubMed: 6644893]
175.
Lopez Pereira P, Somoza I, Martinez Urrutia MJ, Romera L, Jaureguizar E. Can urodynamic studies predict bladder behaviour changes after artificial urinary sphincter implantation? Journal of Pediatric Urology. 2005;1(6):397–401. [PubMed: 18947579]
176.
Lopez Pereira P, Somoza I, Martinez Urrutia MJ, Lobato Romera R, Jaureguizar E. Artificial urinary sphincter: 11-year experience in adolescents with congenital neuropathic bladder. European Urology. 2006;50(5):1096–1101. [PubMed: 16530321]
177.
Murphy S, Rea D, O’Mahony J, McDermott TE, Thornhill J, Butler M, et al. A comparison of the functional durability of the AMS 800 artificial urinary sphincter between cases with and without an underlying neurogenic aetiology. Irish Journal of Medical Science. 2003;172(3):136–138. [PubMed: 14700117]
178.
Murray KH, Nurse DE, Mundy AR. Detrusor behaviour following implantation of the Brantley Scott artificial urinary sphincter for neuropathic incontinence. British Journal of Urology. 1988;61(2):122–128. [PubMed: 3280079]
179.
O’Flynn KJ, Thomas DG. Artificial urinary sphincter insertion in congenital neuropathic bladder. British Journal of Urology. 1991;67(2):155–157. [PubMed: 2004226]
180.
Patki P, Hamid R, Shah PJ, Craggs M. Long-term efficacy of AMS 800 artificial urinary sphincter in male patients with urodynamic stress incontinence due to spinal cord lesion. Spinal Cord. 2006;44(5):297–300. [PubMed: 16249789]
181.
Simeoni J, Guys JM, Mollard P, Buzelin JM, Moscovici J, Bondonny JM, et al. Artificial urinary sphincter implantation for neurogenic bladder: a multi-institutional study in 107 children. British Journal of Urology. 1996;78(2):287–293. [PubMed: 8813930]
182.
Spiess PE, Capolicchio JP, Kiruluta G, Salle JP, Berardinucci G, Corcos J. Is an artificial sphincter the best choice for incontinent boys with spina bifida? Review of our long term experience with the AS-800 artificial sphincter. Canadian Journal of Urology. 2002;9(2):1486–1491. [PubMed: 12010593]
183.
Catto JW, Natarajan V, Tophill PR. Simultaneous augmentation cystoplasty is associated with earlier rather than increased artificial urinary sphincter infection. Journal of Urology. 2005;173(4):1237–1241. [PubMed: 15758760]
184.
Webb DR, Fitzpatrick JM, O’Flynn JD. A 15-year follow-up of 406 consecutive spinal cord injuries. British Journal of Urology. 1984;56(6):614–617. [PubMed: 6534476]
185.
Brindley GS. The first 500 patients with sacral anterior root stimulator implants: general description. Paraplegia. 1994;32(12):795–805. [PubMed: 7708419]
186.
National Institute for Health and Clinical Excellence. Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. London: National Institute for Health and Clinical Excellence; 2010. Available from: http://www​.nice.org.uk​/nicemedia/live/12984/48557/48557.pdf.
187.
Abrams P, Amarenco G, Bakke A, Buczynski A, Castro-Diaz D, Harrison S, et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. Journal of Urology. 2003;170(4 Pt 1):1242–1251. [PubMed: 14501734]
188.
O’Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? Journal of Urology. 1995;153(4):1114–1116. [PubMed: 7869476]
189.
Petersen T, Husted SE, Sidenius P. Prazosin treatment of neurological patients with detrusor hyperreflexia and bladder emptying disability. Scandinavian Journal of Urology and Nephrology. 1989;23(3):189–194. [PubMed: 2678426]
190.
Schulte-Baukloh H. Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. BJU International. 2002;90(7):716–720. [PubMed: 12410754]
191.
NHS Business Services Authority. NHS electronic drug tariff. 2012. [Last accessed: 7 February 2012]. Available from: http://www​.ppa.org.uk​/edt/February_2012/mindex.htm.
192.
Chartier-Kastler E, Mozer P, Denys P, Bitker MO, Haertig A, Richard F. Neurogenic bladder management and cutaneous non-continent ileal conduit. Spinal Cord. 2002;40(9):443–448. [PubMed: 12185605]
193.
de Long J, Tighiouart H, Stoffel J. Urinary diversion/reconstruction for cases of catheter intolerant secondary progressive multiple sclerosis with refractory urinary symptoms. Journal of Urology. 2011;185(6):2201–2206. [PubMed: 21497848]
194.
Flanigan RC, Kursh ED, Persky L. Thirteen year experience with ileal loop diversion in children with myelodysplasia. American Journal of Surgery. 1975;130(5):535–538. [PubMed: 1106240]
195.
Guillotreau J, Castel-Lacanal E, Roumiguie M, Bordier B, Doumerc N, De BX, et al. Prospective study of the impact on quality of life of cystectomy with ileal conduit urinary diversion for neurogenic bladder dysfunction. Neurourology and Urodynamics. 2011;30(8):1503–1506. [PubMed: 21674595]
196.
Kato H, Hosaka K, Kobayashi S, Igawa Y, Nishizawa O. Fate of tetraplegic patients managed by ileal conduit for urinary control: long-term follow-up. International Journal of Urology. 2002;9(5):253–256. [PubMed: 12060437]
197.
Legrand G, Roupret M, Comperat E, Even-Schneider A, Denys P, Chartier-Kastler E. Functional outcomes after management of end-stage neurological bladder dysfunction with ileal conduit in a multiple sclerosis population: a monocentric experience. Urology. 2011;78(4):937–941. [PubMed: 21820707]
198.
Moeller BA. Some observations of 31 spinal cord injury patients on whom the Bricker procedure was performed. Paraplegia. 1977;15(3):230–237. [PubMed: 593713]
199.
Smith HP, Russell JM, Boyce WH, Alexander E Jr. Results of urinary diversion in patients with myelomeningocele. Journal of Neurosurgery. 1979;50(6):773–778. [PubMed: 438878]
200.
Ozel SK, Dokumcu Z, Akyildiz C, Avanoglu A, Ulman I. Factors affecting renal scar development in children with spina bifida. Urologia Internationalis. 2007;79(2):133–136. [PubMed: 17851282]
201.
Biering-Sorensen F, Hoiby N, Nordenbo A, Ravnborg M, Bruun B, Rahm V. Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. Journal of Urology. 1994;151(1):105–108. [PubMed: 8254783]
202.
Duffy L, Smith AD. Nitrofurantoin macrocrystals prevent bacteriuria in intermittent self-catheterization. Urology. 1982;20(1):47–49. [PubMed: 7112797]
203.
Schlager TA, Anderson S, Trudell J, Hendley JO. Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. Journal of Pediatrics. 1998;132(4):704–708. [PubMed: 9580774]
204.
Clarke SA, Samuel M, Boddy SA. Are prophylactic antibiotics necessary with clean intermittent catheterization? A randomized controlled trial. Journal of Pediatric Surgery. 2005;40(3):568–571. [PubMed: 15793737]
205.
Sandock DS, Gothe BG, Bodner DR. Trimethoprim-sulfamethoxazole prophylaxis against urinary tract infection in the chronic spinal cord injury patient. Paraplegia. 1995;33(3):156–160. [PubMed: 7784119]
206.
Zegers B, Uiterwaal C, Kimpen J, Van GJ, De JT, Winkler-Seinstra P, et al. Antibiotic prophylaxis for urinary tract infections in children with spina bifida on intermittent catheterization. Journal of Urology. 2011;186(6):2365–2371. [PubMed: 22019031]
207.
Johnson HW, Anderson JD, Chambers GK, Arnold WJ, Irwin BJ, Brinton JR. A short-term study of nitrofurantoin prophylaxis in children managed with clean intermittent catheterization. Pediatrics. 1994;93(5):752–755. [PubMed: 8165073]
208.
Anderson RU. Prophylaxis of bacteriuria during intermittent catheterization of the acute neurogenic bladder. Journal of Urology. 1980;123(3):364–366. [PubMed: 6244414]
209.
Gribble MJ, Puterman ML. Prophylaxis of urinary tract infection in persons with recent spinal cord injury: a prospective, randomized, double-blind, placebo-controlled study of trimethoprim-sulfamethoxazole. American Journal of Medicine. 1993;95(2):141–152. [PubMed: 8356980]
210.
Lindan R, Joiner E. A prospective study of the efficacy of low dose nitrofurantoin in preventing urinary tract infections in spinal cord injury patients, with comments on the role of pseudomonads. Paraplegia. 1984;22(2):61–65. [PubMed: 6462734]
211.
Maynard FM, Diokno AC. Urinary infection and complications during clean intermittent catheterization following spinal cord injury. Journal of Urology. 1984;132(5):943–946. [PubMed: 6333518]
212.
Mohler JL, Cowen DL, Flanigan RC. Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. Journal of Urology. 1987;138(2):336–340. [PubMed: 3496470]
213.
Darouiche RO, Smith MS, Markowski J. Antibiotic prophylaxis for urodynamic testing in patients with spinal cord injury: a preliminary study. Journal of Hospital Infection. 1994;28(1):57–61. [PubMed: 7806870]
214.
Bodner DR, Witcher M, Resnick MI. Application of office ultrasound in the management of the spinal cord injury patient. Journal of Urology. 1990;143(5):969–972. [PubMed: 2109802]
215.
Calenoff L, Neiman HL, Kaplan PE, Nanninga J, Brandt TD, Hamilton BB. Urosonography in spinal cord injury patients. Journal of Urology. 1982;128(6):1234–1237. [PubMed: 7154175]
216.
Gousse AE, Meinbach DS, Kester RR, Razdan S, Kim SS, Pareek K, et al. Renal ultrasound correlates with renal nuclear scan in upper tract surveillance of spinal cord-injured patients. Topics in Spinal Cord Injury Rehabilitation. 2003;8(3):1–7.
217.
Gupta S, Chawla JC. Review of urinary tract abnormalities in 100 patients with spinal cord paralysis. Paraplegia. 1994;32(8):531–539. [PubMed: 7970858]
218.
Lemack G, Hawker K, Frohman E. Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluation. Urology. 2005;65(5):854–857. [PubMed: 15882710]
219.
MacDiarmid SA, McIntyre WJ, Anthony A, Bailey RR, Turner JG, Arnold EP. Monitoring of renal function in patients with spinal cord injury. BJU International. 2000;85(9):1014–1018. [PubMed: 10848686]
220.
Morcos SK, Thomas DG. A comparison of real-time ultrasonography with intravenous urography in the follow-up of patients with spinal cord injury. Clinical Radiology. 1988;39(1):49–50. [PubMed: 3276431]
221.
Persun ML, Ginsberg PC, Harmon JD, Harkaway RC. Role of urologic evaluation in the adult spina bifida patient. Urologia Internationalis. 1999;62(4):205–208. [PubMed: 10567883]
222.
Sepahpanah F, Burns SP, McKnight B, Yang CC. Role of creatinine clearance as a screening test in persons with spinal cord injury. Archives of Physical Medicine and Rehabilitation. 2006;87(4):524–528. [PubMed: 16571392]
223.
Sliwa JA, Bell HK, Mason KD, Gore RM, Nanninga J, Cohen B. Upper urinary tract abnormalities in multiple sclerosis patients with urinary symptoms. Archives of Physical Medicine and Rehabilitation. 1996;77(3):247–251. [PubMed: 8600866]
224.
Tarcan T, Bauer S, Olmedo E, Khoshbin S, Kelly M, Darbey M. Long-term followup of newborns with myelodysplasia and normal urodynamic findings: is follow-up necessary? Journal of Urology. 2001;165(2):564–567. [PubMed: 11176436]
225.
Tins B, Teo HG, Popuri R, Cassar-Pullicino V, Tyrrell P. Follow-up imaging of the urinary tract in spinal injury patients: is a KUB necessary with every ultrasound? Spinal Cord. 2005;43(4):219–222. [PubMed: 15672096]
226.
Tsai SJ, Ting H, Ho CC, Bih LI. Use of sonography and radioisotope renography to diagnose hydronephrosis in patients with spinal cord injury. Archives of Physical Medicine and Rehabilitation. 2001;82(1):103–106. [PubMed: 11239294]
227.
Vaidyanathan S, Hughes PL, Soni BM. A comparative study of ultrasound examination of urinary tract performed on spinal cord injury patients with no urinary symptoms and spinal cord injury patients with symptoms related to urinary tract: do findings of ultrasound examination lead to changes in clinical management? The Scientific World Journal. 2006;6:2450–2459. [PMC free article: PMC5917309] [PubMed: 17619717]
228.
Waites KB, Canupp KC, DeVivo MJ, Lloyd LK, Dubovsky EV. Compliance with annual urologic evaluations and preservation of renal function in persons with spinal cord injury. Journal of Spinal Cord Medicine. 1995;18(4):251–254. [PubMed: 8591072]
229.
Yang CC, Clowers DE. Screening cystoscopy in chronically catheterized spinal cord injury patients. Spinal Cord. 1999;37(3):204–207. [PubMed: 10213331]
230.
Navon JD, Soliman H, Khonsari F, Ahlering T. Screening cystoscopy and survival of spinal cord injured patients with squamous cell cancer of the bladder. Journal of Urology. 1997;157(6):2109–2111. [PubMed: 9146592]
231.
de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13(7):915–928. [PubMed: 17881401]
232.
Scottish Renal Paediatric Group. Guidelines on the management of neuropathic bladder. Edinburgh; NHS Scotland: 2005.
233.
Bennett C, Young MN, Adkins R, Diaz F. Comparison of bladder management complication outcomes in female spinal cord injury patients. Journal of Urology. 1995;153(5):1458–1460. [PubMed: 7714965]
234.
Cardenas DD, Mayo ME. Bacteriuria with fever after spinal cord injury. Archives of Physical Medicine and Rehabilitation. 1987;68(5 (Pt 1)):291–293. [PubMed: 3579535]
235.
Chen Y, de Vivo MJ, Roseman JM. Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study. Spinal Cord. 2000;38(6):346–353. [PubMed: 10889563]
236.
Dahlberg A, Perttila I, Wuokko E, Ala-Opas M. Bladder management in persons with spinal cord lesion. Spinal Cord. 2004;42(12):694–698. [PubMed: 15365573]
237.
Dewire DM, Owens RS, Anderson GA, Gottlieb MS, Lepor H. A comparison of the urological complications associated with long-term management of quadriplegics with and without chronic indwelling urinary catheters. Journal of Urology. 1992;147(4):1069–1071. [PubMed: 1552585]
238.
Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Archives of Physical Medicine and Rehabilitation. 2002;83(3):346–351. [PubMed: 11887115]
239.
Hansen RB, Biering S, Kristensen JK. Urinary calculi following traumatic spinal cord injury. Scandinavian Journal of Urology and Nephrology. 2007;41(2):115–119. [PubMed: 17454949]
240.
Ku JH, Choi WJ, Lee KY, Jung TY, Lee JK, Park WH, et al. Complications of the upper urinary tract in patients with spinal cord injury: a long-term follow-up study. Urological Research. 2005;33(6):435–439. [PubMed: 16317536]
241.
Ku JH, Jung TY, Lee JK, Park WH, Shim HB. Risk factors for urinary stone formation in men with spinal cord injury: a 17-year follow-up study. BJU International. 2006;97(4):790–793. [PubMed: 16536775]
242.
Larsen LD, Chamberlin DA, Khonsari F, Ahlering TE. Retrospective analysis of urologic complications in male patients with spinal cord injury managed with and without indwelling urinary catheters. Urology. 1997;50(3):418–422. [PubMed: 9301708]
243.
Maynard FM, Diokno AC. Clean intermittent catheterization for spinal cord injury patients. Journal of Urology. 1982;128(3):477–480. [PubMed: 7120549]
244.
McGuire EJ, Savastano J. Comparative urological outcome in women with spinal cord injury. Journal of Urology. 1986;135(4):730–731. [PubMed: 3959193]
245.
Nwadiaro HC, Nnamonu MI, Ramyil VM, Igun GO. Comparative analysis of urethral catheterization versus suprapubic cystostomy in management of neurogenic bladder in spinal injured patients. Nigerian Journal of Medicine. 2007;16(4):318–321. [PubMed: 18080587]
246.
Ord J, Lunn D, Reynard J. Bladder management and risk of bladder stone formation in spinal cord injured patients. Journal of Urology. 2003;170(5):1734–1737. [PubMed: 14532765]
247.
Sugimura T, Arnold E, English S, Moore J. Chronic suprapubic catheterization in the management of patients with spinal cord injuries: analysis of upper and lower urinary tract complications. BJU International. 2008;101(11):1396–1400. [PubMed: 18190633]
248.
Waites KB, Canupp KC, DeVivo MJ. Epidemiology and risk factors for urinary tract infection following spinal cord injury. Archives of Physical Medicine and Rehabilitation. 1993;74(7):691–695. [PubMed: 8328888]
249.
Weld KJ, Dmochowski R. Effect of bladder management on urological complications in spinal cord injured patients. Journal of Urology. 2000;163(3):768–772. [PubMed: 10687973]
250.
Lindehall B, ller A, Hjalmas K, Jodal U, Abrahamsson K. Psychosocial factors in teenagers and young adults with myelomeningocele and clean intermittent catheterization. Scandinavian Journal of Urology and Nephrology. 2008;42(6):539–544. [PubMed: 19031268]
251.
Oh SJ, Ku JH, Jeon HG, Shin HI, Paik NJ, Yoo T. Health-related quality of life of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Urology. 2005;65(2):306–310. [PubMed: 15708043]
252.
Pannek J, Kullik B. Does optimizing bladder management equal optimizing quality of life? Correlation between health-related quality of life and urodynamic parameters in patients with spinal cord lesions. Urology. 2009;74(2):263–266. [PubMed: 19428089]
253.
van der Eijk M, Faber MJ, Al SS, Munneke M, Bloem BR. Moving towards patient-centered healthcare for patients with Parkinson’s disease. Parkinsonism and Related Disorders. 2011;17(5):360–364. [PubMed: 21396874]
254.
Wollin J, Bennie M, Leech C, Windsor C, Spencer N. Multiple sclerosis and continence issues: an exploratory study. British Journal of Nursing. 2005;14(8):439–440. [PubMed: 15924024]
255.
Multiple Sclerosis Society; Motor Neurone Disease Association; Parkinson’s UK; Ataxia UK. Quality Neurology: report to the Department of Health. London: Neurological Commissioning Support Limited (NCS Ltd); 2009.
256.
Johnson J, Smith P, Goldstone L. Evaluation of MS Specialist Nurses: a review and development of the role. Letchworth Garden City: MS Trust; 2001.
257.
Sawyer SM, Collins N, Bryan D, Brown D, Hope MA, Bowes G. Young people with spina bifida: transfer from paediatric to adult health care. Journal of Paediatrics and Child Health. 1998;34(5):414–417. [PubMed: 9767501]
258.
Lotstein DS, McPherson M, Strickland B, Newacheck PW. Transition planning for youth with special health care needs: results from the National Survey of Children with Special Health Care Needs. Pediatrics. 2005;115(6):1562–1568. [PubMed: 15930217]
259.
Duke NN, Scal PB. Adult care transitioning for adolescents with special health care needs: a pivotal role for family centered care. Maternal and Child Health Journal. 2011;15(1):98–105. [PubMed: 20012347]
260.
Scal P, Ireland M. Addressing transition to adult health care for adolescents with special health care needs. Pediatrics. 2005;115(6):1607–1612. [PubMed: 15930223]
261.
Osterlund CS, Dosa NP, Arnott-Smith C. Mother knows best: medical record management for patients with spina bifida during the transition from pediatric to adult care. Annual Symposium Proceedings/AMIA Symposium. 2005:580–584. [PMC free article: PMC1560796] [PubMed: 16779106]
262.
Davies H, Rennick J, Majnemer A. Transition from pediatric to adult health care for young adults with neurological disorders: parental perspectives. Canadian Journal of Neuroscience Nursing. 2011;33(2):32–39. [PubMed: 21977770]
263.
Fiorentino L, Phillips D, Walker A, Hall D. Leaving paediatrics: the experience of service transition for young disabled people and their family carers. Health and Social Care in the Community. 1998;6(4):260–270. [PubMed: 11560598]
264.
Reiss JG, Gibson RW, Walker LR. Health care transition: youth, family, and provider perspectives. Pediatrics. 2005;115(1):112–120. [PubMed: 15629990]
265.
Stewart DA, Law MC, Rosenbaum P, Willms DG. A qualitative study of the transition to adulthood for youth with physical disabilities. Physical and Occupational Therapy in Pediatrics. 2001;21(4):3–21. [PubMed: 12043171]
266.
Young NL, Barden WS, Mills WA, Burke TA, Law M, Boydell K. Transition to adult-oriented health care: perspectives of youth and adults with complex physical disabilities. Physical and Occupational Therapy in Pediatrics. 2009;29(4):345–361. [PubMed: 19916821]
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

Bookshelf ID: NBK132844

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (3.7M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...